Share
August 2019 News from Champions Oncology

Covering a full range of research and development solutions that help guide decision making for clinical oncology drug development, here's where you can stay up-to-date on news, events, and special opportunities for study enrollment.
Champions 7 Model Synscreen Large Scale Syngeneic Screen
- Now Enrolling

*Now Available with up to 16 Channel Flow Cytometry Analysis


Enroll in our upcoming Synscreen with substantial cost savings vs standalone studies.

Syngeneic lines:

- MC38, CT26, LLC, RENCA, B16F10, 4T1, EMT6

- All models characterized for checkpoint inhibitor response
- FREE Control Group and 50% off checkpoint inhibitor SoC arms

Limited availability, enrollment closes September 30th, 2019.

New Free-to-Access PDX NGS Data


An additional 24 new models with Whole Exome and RNA Sequencing have now been added to Champions TumorGraft Database.

Models include;

BRCA1/2 pathological mutations
FGFR1-4 mutations, fusion
ROS1 mutation
Androgen Receptor, ESR1 mut

There are now >800 model available for study with NGS data. Access our online database here.

Coming Soon - Primary Patient AML In Vitro Screen

Champions upcoming AML In Vitroscreen will soon be announced. Screen large cohorts of Primary AML Models which have never been passaged in vivo.

Models have been characterized for:

- In Vitro proliferation and AraC dose response
- Clinical and Targeted Sequencing Information

End point is either Cell Titer Glo or Flow Cytometry read out.
Additional information on Champions' AML In Vitro Screen can be found here.

PBMC Humanized Studies

Champions now offers PBMC humanized studies for T-cell directed therapeutics including bi-specific antibodies. When engrafted with human cell lines or PDX models, this platform is ideally suited to test human-specific immuno-oncology agents.

Together with our flow cytometry expertise and luminex cytokine assays PD markers can be assessed in addition to tumor growth inhibition. Find out more here.


Champions Oncology 1st Annual Boston Symposium: Current Trends in Translational Oncology


Thursday, September 19, 2019 at Museum of Science
September 19th 2019, 7:30AM-4PM Sessions, 4PM – 5:30PM Reception


Join Boston’s leading oncology innovators. Learn from experts about their current therapeutic approach to today’s oncology challenges. Gain insight on how to further support your oncology and immuno-oncology drug development programs, from preclinical and translational studies, to research in the clinic, by attending the Champions Oncology drug discovery symposium.

Free to attend, limited spaces available - sign up here
Please contact Michelle Mack today at mmack@championsoncology.com or
585-305-2453 for more information
Copyright © 2019, All rights reserved.

Our mailing address is:
Corporate Headquarters
One University Plaza
Suite 307
Hackensack, NJ 07601

Champions TumorGraft is a registered trademark of Champions Oncology
 
 

Email Marketing by ActiveCampaign